Articles

TransMedics transforms transplants

TransMedics, Inc. receives FDA Pre-Market Approval for its OCS Lung System for Transplantation
Written byMel J. Yeates
| 2 min read

ANDOVER, Mass.—TransMedics, Inc., a medical technology company focused in portable ex-vivo warm perfusion and assessment of donor organs for transplantation in patients with end-stage lung, heart and liver failure, has announced today that the U.S. Food and Drug Administration (FDA) approved its Pre-Market Approval Application (PMA) for the Organ Care System (OCS) Lung platform for the standard double lung transplant indication on March 22, 2018.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
Blue microscopic illustration of spherical cells with textured surfaces against a dark background.
Explore how longitudinal single-cell profiling of whole blood can reveal immune signatures associated with CAR T cell therapy-related neurotoxicity.